KUSURINOMADOGUCHI INC

Company Overview

Kusurinomadoguchi is a Japanese healthcare IT platform centered on pharmacies, with expansion into clinics and care facilities. It started as the pharmacy arm of the EPARK ecosystem and now sells tools that help pharmacies win patients, receive prescriptions online, manage repeat users, negotiate drug procurement, automate inventory, and run core operating systems.

Data freshness matters here. The latest clean official annual base is FY2025. More recent data is partial, delayed, unaudited, or estimated. Specifically, FY2026 full-year results were disclosed on 2026-05-14 in a full-year earnings release, but the FY2026 annual securities report is not the clean audited base used here.

Growth has been driven by two concrete engines. First, the installed base and usage keep expanding: total customer count rose from 31,631 in FY2023 to 44,393 in FY2025 and 53,441 in FY2026. Second, recurring monetization is improving: March ARPU rose from JPY 14.5k in FY2023 to JPY 15.9k in FY2026, while prescription reservation volume and pharmacy transaction revenue kept climbing.

A rough owner-earnings sanity check, using a simplified approach rather than a strict Buffett reconstruction, is: reported FY2026 net income of JPY 2.95bn, less my estimate of sustaining software capex of roughly JPY 1.0-1.2bn, with working capital treated as roughly neutral on a normalized basis after the FY2025 settlement-scheme distortion, gives owner earnings of about JPY 1.7-1.9bn. That is an owner-earnings yield of roughly 5.8-6.5% on today’s market cap. Yes, that is materially less flattering than the headline P/E, because reported earnings benefited from tax items and because capitalized software is a real economic cost.

Capital efficiency looks good but not pristine. Reported ROE moved from 15.2% in FY2023 to 19.2% in FY2024, 27.5% in FY2025, and 29.8% on FY2026 earnings-release figures. Reported ROIC is in the low-20% range. That says the core business has earned high returns on incremental capital, but the true picture is somewhat less clean than those headline ratios imply because tax assets, M&A, and capitalized development all help the optics.

Business quality is decent. Profits actually come from recurring pharmacy workflow revenue, not from flashy consumer traffic. The company has been a good business because it sits inside a regulated and inconvenient workflow where pharmacies care about patient acquisition, pharmacist labor, inventory waste, and reimbursement complexity. That creates stickiness. But this is not a fortress moat: some modules are replaceable, and the economic moat is more workflow embedding and distribution than unique technology.

How the Company Makes Money

The company reports as one segment, but economically it has three very different quality buckets and one small add-on business.

• Media business: EPARK Kusuri no Madoguchi and EPARK Okusuri Techo. This is the patient-facing and pharmacy-acquisition engine. Revenue comes from prescription reservation fees, monthly plans, customer-management tools, and related services.
• Minna no Oyakubako business: procurement support, dead-stock medicine matching, and inventory ordering tools. Revenue comes from monthly fees and transaction-linked fees tied to drug purchasing and inventory flow.
• Core systems business: pharmacy, clinic, and care-facility systems. This includes installation revenue and maintenance/support. It broadens the bundle, but it is lower-quality than the first two because it is more exposed to subsidy cycles and one-off project revenue.
• Preventive health / other: still small.

The key distinction is stock revenue versus shot revenue. In FY2026, stock revenue was JPY 8.57bn, or 69.5% of total sales, while shot revenue fell 5%. That tells you the economic engine is recurring usage and subscription-like revenue, not one-off installs.

Where do profits actually come from? Mainly from the recurring gross profit of the media and procurement/inventory platforms. In management’s FY2026 earnings-release presentation, media revenue grew about 15% and Minna no Oyakubako revenue about 13%, while the core systems business slipped about 1% because prior-year subsidy demand rolled off. In other words, the better business is the pharmacy network and workflow layer; the systems rollout business is useful, but not the main reason to own the stock.

Two post-FY2025 events matter. First, the company added Medi-Web and E-Delight in January 2026, which expands its presence in the clinic market and helped fourth-quarter growth. Second, on 2026-06-05 it authorized a buyback of up to 115,000 shares, or JPY 300m. The buyback helps capital-allocation optics, but it is small and does not change the economics.

Why the Stock Fell

The stock fell because investors stopped trusting the quality and durability of the numbers, not because reported earnings missed. After reaching JPY 4,685 in late September 2025, the shares fell to JPY 2,389 by 2026-03-30. Recent trading around JPY 2,560 still leaves the stock roughly 45% below the peak and only modestly above the low.

What is striking is that this decline happened while the company was upgrading guidance. Management raised FY2026 guidance in February 2026 and again in April 2026, then delivered FY2026 revenue up 10% and operating profit up 37% in the May 2026 earnings release. When a stock drops despite stronger numbers, the market is usually saying one of three things: the earnings are not clean, the growth is not durable, or the shareholder base is going to create supply pressure.

• Investors saw the ugly FY2025 operating cash flow print and questioned earnings quality.
• Investors worried that some of the growth, especially in systems, was boosted by subsidy-related demand that would not repeat.
• Investors worried about ownership concentration, low float, and stock overhang from large holders.
• Investors also had reason to suspect that the strongest recent quarter was helped by M&A, not just organic momentum.

What the Market Is Assuming

(a) One-time / cyclical / sentiment-driven factors

• The FY2025 cash-flow collapse means reported earnings are not real.
• The stock will stay cheap because large shareholders will keep feeding stock into the market.
• The company’s previous listing-standard issue on free float signaled weak institutional quality.

(b) Medium-term business headwinds

• The core systems business is coming off a subsidy and reimbursement-cycle tailwind.
• Growth is getting less organic and more dependent on acquisitions and new product launches.
• Pharmacy customers face reimbursement pressure, which could limit ARPU expansion.

(c) Potential long-term structural threats

• The EPARK relationship is part of the customer-acquisition funnel and brand architecture.
• The moat may be only moderate because specialist competitors can attack modules one by one.
• A serious data breach or system outage would directly damage trust in a health-data workflow business.

Reality check versus the narrative. The company does not disclose ARR or churn, so the best cross-check is recurring revenue, customer count, margins, cash flow, and balance-sheet trend. FY2025 and earlier are audited annual data; FY2026 figures below are from the unaudited full-year earnings release.

Temporary or Structural?

Diagnosis: mostly TIME, not ESSENCE. The stock’s problems are more severe than a normal sentiment wobble, but the current evidence does not show that the core value-creation mechanism has broken. The real structural questions are narrower.

The key point is that none of these structural risks is currently showing up as observable damage in reservations, customer count, recurring revenue, margin, or leverage. The most important thing the market is right to worry about is earnings quality. But that is a valuation issue more than a moat-break issue.

Is the Market Wrong? By How Much?

Time-as-a-moat test. If I had the company’s current market capitalization in cash, I could build software. I could not quickly rebuild the distribution, integrations, and installed base.

• Within 2 years: No. You would not realistically rebuild the pharmacy relationships, data integrations, reservation traffic, app habit, and workflow trust.
• Within 5 years: Partially. A strong strategic could build or buy modules, especially in clinic and systems software, but recreating dense pharmacy coverage and daily workflow usage would still be hard.
• Within 10 years: Probably yes, especially for a larger strategic with capital and distribution. What would still block you is not the code; it is the network of pharmacy locations, the operational data, the customer relationships, and the trust embedded in regulated workflows.

So the moat is real, but it is a time-and-integration moat, not an impregnable technology moat.

Valuation basis. This valuation uses FY2026 full-year earnings-release numbers as the current operating run-rate, but it adjusts them using FY2025 audited cash-flow context and my own normalization of tax benefits and sustaining software spend. I do not treat the headline FY2026 net income as clean earning power.

This is an intrinsic value estimate, not a price target. I am not assuming multiple expansion. The bridge is simply normalized owner earnings, a required equity yield, and a modest net-cash adjustment.

At roughly JPY 2,560 per share, the market is implying about a 6.8% owner-earnings yield on my base estimate. That is only slightly better than the roughly 7% yield I would want for a small-cap, founder-influenced, moderate-moat healthcare IT business with some acquisition, related-party, and accounting-quality risk. In plain terms: the market is probably too pessimistic about what is wrong, but not wildly wrong about how much the stock is worth.

Key Facts, Estimates, and Judgments

Moat & Mispricing Score: 6/10. The market is too negative on the nature of the problem. Recurring revenue, customer count, margins, and balance-sheet strength all argue against a broken franchise. But the market is not missing the central accounting issue: the headline 9.9x P/E is optically cheap because tax benefits and capitalized software flatter reported earnings. My base intrinsic value is only about JPY 2,670 per share versus a current price around JPY 2,560, so the mispricing exists, but it is mild rather than dramatic.